Pharma major Ranbaxy Laboratories Ltd on Friday entered into an in-licensing agreement with Gilead Sciences to promote access to low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries.

Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs, Ranbaxy said in a filing to the Bombay Stock Exchange.

“The association with Gilead will enable us to offer quality, affordable medicines for treatment of HIV/ AIDS in the developing countries,” Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy said.

The company would sell single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

(This article was published on August 3, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.